Navigation Links
Lilly Receives NCQA Design Certification for Depression Care Management Program
Date:11/6/2007

INDIANAPOLIS, Nov. 6 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY) has received Program Design Certification from the National Committee for Quality Assurance (NCQA) for its Tools that Empower(TM) Depression Care Management Program.

Tools that Empower(TM) Depression Care Management Program is designed for managed care organizations to assist in further driving the standard of patient care around Major Depressive Disorder (MDD). Lilly created the program in response to the growing population of patients diagnosed with MDD.

Developed by experts in MDD management, including practicing psychiatrists and psychologists, clinical research experts, managed care medical directors and mental health specialty physicians, Tools that Empower helps identify members with MDD and offers educational resources to support treatment. In addition, the program helps enroll members, perform clinical screening and clinical risk stratification; offers interventions based on member clinical risk; executes program satisfaction assessment and outcomes measurement; and provides a comprehensive list of MDD resources.

The foundation of this program is based upon the APA Standards of Care for major depressive disorder, the HEDIS(R) measure for Antidepressant Medication Management, and several other related, peer-reviewed articles.

NCQA certification is an indication that a disease management program has passed a rigorous review in a specific area, either program design, patient contact or disease management systems. According to NCQA, certification standards are purposely set high to encourage organizations to continuously enhance their quality.

"Disease management offers tremendous promise for improving the care received by the chronically ill," said Margaret E. O'Kane, president of NCQA. "By achieving NCQA DM Certification, an organization is showing that it is ready to provide specific services that can help fulfill that promise."

Offering relevant, non-branded interventions that are based on the most recent clinical research and findings is an example of how Lilly seeks to meet the needs of patients.

"Tools that Empower is part of Lilly's commitment to our customers to help reduce patient risk and create an environment of continuous improvement for patient care," said Jack Bailey, vice president, Lilly's Business to Business division. "The NCQA certification validates the helpful tools provided by the program."

Disease Management Certification is based on a review of disease management content - such as printed, electronic and in-person methods for working with patients and practitioners - according to clinical guidelines. NCQA has reviewed and certified Lilly's Program Design capability. For complete details on the scope of this review, visit http://www.lilly.com.

Lilly also offers several other NCQA Design Certified programs as part of its ongoing commitment to improving patient safety and quality. They include:

-- Tools That Empower(TM) Diabetes Management Program, a robust diabetes

disease management program that contains more than 20 best-in-class

tools and resources for care managers and diabetes program directors.

-- HealthInsights for Women, a disease management program that targets

women 30 years and older about disease risk factors, and inspires them

to make behavior changes that can lead to better health.

-- Health Evaluator for Lilly Partners (HELP), a comprehensive,

interactive online resource for patients that is flexible, customizable

and secure.

-- Expanding Views: Achieving more with ADHD, reinforces the importance

of providing follow-up care for patients with

attention-deficit/hyperactivity disorder (ADHD) based upon the HEDIS(R)

measure.

About NCQA:

NCQA is a private, non-profit organization dedicated to improving healthcare quality. NCQA is committed to providing healthcare quality information through the Web and the media in order to help consumers, employers and others make more informed healthcare choices.

Consumers can access an organization's NCQA Accreditation and Certification status and other information on healthcare quality on NCQA's Web site at http://www.ncqa.org, or by calling NCQA Customer Support at (888) 275-7585.

About Lilly:

Lilly, a leading innovation-driven corporation, is developing a growing portfolio of first-in-class and best-in-class pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers -- through medicines and information -- for some of the world's most urgent medical needs. Additional information about Lilly is available at http://www.lilly.com.

HEDIS (Healthcare Effectiveness Data and Information Set) is a registered trademark of the National Committee for Quality Assurance. Tools that Empower is a trademark of Eli Lilly and Company.

C-LLY

(Logo: http://www.newscom.com/cgi-bin/prnh/20031219/LLYLOGO )


'/>"/>
SOURCE Eli Lilly and Company
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
3. Lilly and Glenmark Pharmaceuticals Announce License Agreement
4. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
5. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
6. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
7. Abbott Receives Supplemental FDA Approval for its Best-in-Class in Sensitivity RealTime HIV-1 Viral Load Test
8. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
9. CryoCor Receives FDA Approval for Right Atrial Flutter
10. Ranbaxy Receives Approval to Manufacture and Market Hydrocodone Bitartrate and Acetaminophen Tablets USP
11. Dimericine(R) Receives FDA Fast Track Designation for Treatment Of Photosensitivity in XP Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... , April 28, 2016   Click here ... Pharmacy, Inc. (NYSE: DPLO), the nation,s largest independent ... a definitive agreement to acquire Valley Campus Pharmacy, ... ("TNH"), a leading specialty pharmacy that provides individualized ... California . In 2015, TNH generated approximately ...
(Date:4/28/2016)... April 28, 2016  The blood testing market in ... according to Kalorama Information and The Freedonia Group in ... nucleic acid testing.  The healthcare research firm said that ... developing blood collection stations and in improving testing at ... Information,s report, Blood Testing Market in China ...
(Date:4/28/2016)... 28, 2016   Acsis , a leading provider ... IT market research and advisory firm IDC has named ... MarketScape: Worldwide Pharmaceutical Track and Trace Software 2016 Vendor ... an assessment of the capabilities and business strategies of ... market. Logo - http://photos.prnewswire.com/prnh/20160427/360791LOGO ...
Breaking Medicine Technology:
(Date:4/29/2016)... ... April 29, 2016 , ... The Gluten-Free Certification Program ... to announce the launch of the GFCP Scoop in response to ... purpose of the GFCP Scoop site is to keep the gluten-free ...
(Date:4/29/2016)... ... April 29, 2016 , ... Dr. Robert Mondavi, one of the ... Cosmetic dentistry is a fast-growing field as more patients are discovering the many different ... more about the options currently available to them and which ones might work for ...
(Date:4/29/2016)... , ... April 29, 2016 , ... Reltok Nasal Products ... products for the head and neck/ear, nose and throat specialty, has added the KOTLER ... The KOTLER NASAL AIRWAY™ is a newly patented safety device secured by nasal ...
(Date:4/29/2016)... ... April 29, 2016 , ... Jvion, ... round of funding led by Eastside Partners, with participation from existing investor Martin ... customer base and accelerate its technology and product roadmap. , “Jvion ...
(Date:4/29/2016)... ... 2016 , ... Regenerative Medicine Solutions (RMS) scored 94.8124 out of ... them second place for Tampa’s Best Places to Work. They were ranked in the ... great accomplishment for our team,” says RMS Human Resources Manager Irene Miller. “We work ...
Breaking Medicine News(10 mins):